- Home
- NIVF vs PRPO Comparison
NIVF vs PRPO Comparison
Compare NIVF & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- PRPO
- Stock Information
- Founded
- NIVF 2011
- PRPO N/A
- Country
- NIVF Thailand
- PRPO United States
- Employees
- NIVF N/A
- PRPO 57
- Industry
- NIVF
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- NIVF
- PRPO Industrials
- Exchange
- NIVF NYSE
- PRPO Nasdaq
- Market Cap
- NIVF 12.2M
- PRPO 9.5M
- IPO Year
- NIVF N/A
- PRPO N/A
- Fundamental
- Price
- NIVF $1.16
- PRPO $6.59
- Analyst Decision
- NIVF
- PRPO
- Analyst Count
- NIVF 0
- PRPO 0
- Target Price
- NIVF N/A
- PRPO N/A
- AVG Volume (30 Days)
- NIVF 11.9M
- PRPO 7.9K
- Earning Date
- NIVF 11-16-2024
- PRPO 11-11-2024
- Dividend Yield
- NIVF N/A
- PRPO N/A
- EPS Growth
- NIVF N/A
- PRPO N/A
- EPS
- NIVF 0.21
- PRPO N/A
- Revenue
- NIVF $5,136,153.00
- PRPO $16,719,999.00
- Revenue This Year
- NIVF N/A
- PRPO $75.18
- Revenue Next Year
- NIVF N/A
- PRPO N/A
- P/E Ratio
- NIVF $5.39
- PRPO N/A
- Revenue Growth
- NIVF N/A
- PRPO 52.61
- 52 Week Low
- NIVF $0.55
- PRPO $4.31
- 52 Week High
- NIVF $17.24
- PRPO $8.99
- Technical
- Relative Strength Index (RSI)
- NIVF 56.42
- PRPO 52.82
- Support Level
- NIVF $1.07
- PRPO $6.42
- Resistance Level
- NIVF $3.28
- PRPO $6.99
- Average True Range (ATR)
- NIVF 0.42
- PRPO 0.33
- MACD
- NIVF 0.05
- PRPO -0.04
- Stochastic Oscillator
- NIVF 22.42
- PRPO 69.91
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.